Activity of the dolastatin analogue, LU103793, in malignant melanoma

Annals of Oncology

Volumn 12, Issue 4, 2001, Pages 509-511

  Smyth, J ^a   Boneterre, M E ^b   Schellens, J ^c   Calvert, H ^d   Greim, G ^e   Wanders, J ^f   Hanauske, A ^g  

^a WESTERN GENERAL HOSPITAL   (United Kingdom)

^b CENTRE OSCAR LAMBRET   (France)

^c ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

^d NEWCASTLE GENERAL HOSPITAL   (United Kingdom)

^e KLINIKUM NÜRNBERG   (Germany)

^f VU UNIVERSITY AMSTERDAM   (Netherlands)

^g TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Dolastatin; LU103793; Melanoma; Phase II

Indexed keywords

CEMADOTIN; HEMOGLOBIN;

ADULT; AGED; ALOPECIA; ARTICLE; ASTHENIA; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ACTIVITY; DRUG ACTIVITY; DRUG RESPONSE; FEMALE; HEART ARRHYTHMIA; HEMOGLOBIN DETERMINATION; HUMAN; HYPERTENSION; LEUKOPENIA; MAJOR CLINICAL STUDY; MALAISE; MALE; MELANOMA; METASTASIS; NAUSEA AND VOMITING; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SIDE EFFECT; SKIN TOXICITY; THROMBOCYTOPENIA; VOMITING;

EID: 0035008045     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1011194910571     Document Type: Article

References (6)

1. Pettit GR, Kamano Y, Fujii Y et al. Marine animal biosynthetic constituents for cancer chemotherapy. J Nat Prod 1981; 44: 482-5.
2. Pettit GR, Kamano Y, Herald CL et al. The isolation and structure of a remarkable marine antineoplastic constituent: Dolastatin 10. J Am Chem Soc 1987; 109: 6883-5.
3. Bai R, Pettit GR, Hamel E. Dolastatin 10, a poweful cytostatic peptide derived from a marine animal. Inhibition of tubulin polymerisation mediated through the vinca alkaloid binding doman. Biochem Pharmacol 1990; 39: 1941-9.
4. Bai R, Friedman SJ, Pettit GR, Hamel E. Dolastatin 15, a potent antimitotic depsipeptide derived from dolabella auricularia. Interaction with tubulin and effects on cellular microtubules. Biochem Pharmacol 1992; 43: 2637-45.
5. Smith P, Nelson C, Janssen B et al. Pre-clinical antitumour activity of a novel water-soluble dolastatin 15 analogue (LU103793). Proc Am Assoc Cancer Res 1995; 36: 393 (Abstr 2345).
6. Villalona-Calero MA, Baker SD, Hammond L et al. Phase I and pharmacokinetic study of the water-soluble dolastatin 15 analogue LU103793 in patients with advanced solid malignancies. J Clin Oncol 1998; 16 (8): 2770-9.